HPE
68
-3
PNR
72
-3
GLW
57
-3
TSN
30
-10
BAX
48
-2
IR
74
-3
A
51
-7
MMC
55
-2
NFLX
76
2
FRT
58
-5
PPG
50
-4
INTC
28
-7
DVA
50
-4
QRVO
71
3
ZTS
25
-8
EXPD
32
-2
PLD
35
-5
FCX
44
-3
EA
50
-2
AA
56
2
HPE
68
-3
PNR
72
-3
GLW
57
-3
TSN
30
-10
BAX
48
-2
IR
74
-3
A
51
-7
MMC
55
-2
NFLX
76
2
FRT
58
-5
PPG
50
-4
INTC
28
-7
DVA
50
-4
QRVO
71
3
ZTS
25
-8
EXPD
32
-2
PLD
35
-5
FCX
44
-3
EA
50
-2
AA
56
2
Financhill
Back

NanoVibronix 10K Form

Sell
30

NAOV
NanoVibronix

Last Price:
$1.40
Seasonality Move:
8.94%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NAOV News And Ratings

See the #1 stock for the next 7 days that we like better than NAOV

NAOV Financial Statistics

Sales & Book Value

Annual Sales: $2.6M
Cash Flow: $-836K
Price / Cash Flow: 0
Annual Sales: $0.67
Price / Book: 5.03

Profitability

EPS (TTM): -1.23000
Net Income (TTM): $-3.1M
Gross Margin: $1.5M
Return on Equity: -91.36%
Return on Assets: -50.36%

NanoVibronix Earnings Forecast

Key NanoVibronix Financial Ratios

  • The Gross Profit Margin over the past 14 years for NAOV is 58.95%.
  • The Selling, General & Administrative Expenses for NAOV have been equal to 163.45% of Gross Profit Margin.
  • The Research & Development expenses have been 35.54% of Revenue.
  • The Net Earning history of NAOV is -144.84% of Total Revenues.
  • Per Share Earnings over the last 14 years have been positive in 7 years.

NanoVibronix Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: NAOV
CUSIP: 63008J
Website: nanovibronix.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.74
Quick Ratio: 0.84

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NAOV Technical Analysis vs Fundamental Analysis

Sell
30
NanoVibronix (NAOV) is a Sell

Is NanoVibronix a Buy or a Sell?

  • NanoVibronix stock is rated a Sell
    The current NanoVibronix [NAOV] share price is $3.82. The Score for NAOV is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.